Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593074 | 1.00 | KDM4E (0.44) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL19540679 | 0.84 | KDM4E (0.41) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL20988371 | 0.83 | KDM4E (0.42) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL10068335 | 0.83 | BRD4 (0.47) | KDM4EKMT2AMEN1HPGDLMNA | |
| SCHEMBL15741895 | 0.82 | KMT2A (0.51) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL29370451 | 0.82 | KMT2A (0.51) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL24994526 | 0.82 | KDM4E (0.39) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL22877378 | 0.81 | KDM4E (0.41) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL23528888 | 0.80 | KDM4E (0.40) | KDM4EKMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL23528887 | 0.80 | KDM4E (0.40) | KDM4EKMT2AATML3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903488-B | Synthesis method of aforana | 济南久隆医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116903488-A | Synthesis method of aforana | 济南久隆医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230303482-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY | 2023-09-28 | — | — | US | disclosed |
| US-20230303482-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY | 2023-09-28 | — | — | US | disclosed |
| US-20230303482-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY | 2023-09-28 | — | — | US | disclosed |
| EP-3150575-B1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | DU PONT (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3150575-B1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | DU PONT (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11613516-B2 | Method for preparing 2-amino-n-(2,2,2-trifluoroethyl) acetamide | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| US-11324220-B2 | Process for the preparation of isoxazoline compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-113651765-A | Synthesis of afurana | 江苏君若药业有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-8546618-B2 | Method for preparing 3-trifluoromethyl chalcones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8513431-B2 | Method for preparing 5-haloalkyl-4, 5-dihydroisoxazole derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2621894-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130165663-A9 | METHOD FOR PREPARING 5-HALOALKYL-4, 5-DIHYDROISOXAZOLE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120277442-A1 | METHOD FOR PREPARING 5-HALOALKYL-4, 5-DIHYDROISOXAZOLE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8217180-B2 | Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2012047543-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047543-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20110009638-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20100249424-A1 | METHOD FOR PREPARING 5-HALOALKYL-4,5-DIHYDROISOXAZOLE DERIVATIVES | E.I.DUPONT DE NEMOURS AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303482-A1 | METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE | NAAA, SAT1, NAA15 | KDM4E 547/4885KMT2A 266/4885ATM 1315/4885 |
| US-20130165663-A9 | METHOD FOR PREPARING 5-HALOALKYL-4, 5-DIHYDROISOXAZOLE DERIVATIVES | PRDX2, PRXL2A, PRDX1 | KDM4E 2043/4885KMT2A 2294/4885ATM 4809/4885 |
| US-20110009638-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | NR3C2, CYP4A11, RAE1 | KDM4E 313/4885KMT2A 2428/4885ATM 2932/4885 |
| US-11613516-B2 | Method for preparing 2-amino-n-(2,2,2-trifluoroethyl) acetamide | NAAA, SAT1, NAA15 | KDM4E 507/4885KMT2A 268/4885ATM 1263/4885 |
| US-20100249424-A1 | METHOD FOR PREPARING 5-HALOALKYL-4,5-DIHYDROISOXAZOLE DERIVATIVES | PRDX2, PRXL2A, PRDX1 | KDM4E 2043/4885KMT2A 2294/4885ATM 4809/4885 |
| US-11324220-B2 | Process for the preparation of isoxazoline compounds | CYP3A7, CYP3A4, CYP3A5 | KDM4E 1810/4885KMT2A 1079/4885ATM 3058/4885 |
| US-20120277442-A1 | METHOD FOR PREPARING 5-HALOALKYL-4, 5-DIHYDROISOXAZOLE DERIVATIVES | PRDX2, PRXL2A, PRDX1 | KDM4E 2043/4885KMT2A 2294/4885ATM 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.